{"id":2459,"date":"2020-12-22T01:30:10","date_gmt":"2020-12-22T01:30:10","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=2459"},"modified":"2023-08-29T17:48:04","modified_gmt":"2023-08-29T17:48:04","slug":"alterity-therapeutics-commercialise-technology-breaks-antibiotic-resistance","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=2459","title":{"rendered":"Alterity Therapeutics\u5c06\u6253\u7834\u6297\u751f\u7d20\u8010\u836f\u6027\u7684\u6280\u672f\u5546\u4e1a\u5316"},"content":{"rendered":"<p>\u8fd1\u65e5\uff0c\u6606\u58eb\u5170\u5927\u5b66\u7684\u5546\u7528\u8f66\u8f86UniQuest\u83b7\u5f97\u8bb8\u53ef\uff0c\u5141\u8bb8<a href=\"http:\/\/smallcaps-production.test\/stocks\/?symbol=ATH&amp;lang=cn\">Alterity Therapeutics (ASX: ATH)<\/a>\u4f7f\u7528\u5176\u950c\u79bb\u5b50\u8f7d\u4f53\u6280\u672f\u5bf9\u6297\u8d85\u7ea7\u7ec6\u83cc\u3002<\/p>\n<p>UniQuest\u6388\u4e88Alterity\u5168\u7403\u72ec\u5bb6\u6743\u5229\uff0c\u4f7f\u7528\u5176\u950c\u79bb\u5b50\u8f7d\u4f53\u6280\u672f\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u65b9\u6cd5\uff0c\u4f7f\u7ec6\u83cc\u5bf9\u6297\u751f\u7d20\u91cd\u65b0\u654f\u611f\u3002<\/p>\n<p>\u4e00\u65e6Alterity\u5f00\u59cb\u4ece\u8fd9\u9879\u6280\u672f\u7684\u5546\u4e1a\u5316\u4e2d\u83b7\u5f97\u5546\u4e1a\u6536\u5165\uff0c\u5b83\u5c06\u5411UniQuest\u652f\u4ed8\u91cc\u7a0b\u7891\u5f0f\u7684\u8d39\u7528\u548c\u4e0e\u5b66\u672f\u8bb8\u53ef\u76f8\u79f0\u7684\u7248\u7a0e\u3002<\/p>\n<p>Alterity\u5c06\u7ed3\u5408PBT2\u950c\u79bb\u5b50\u8f7d\u4f53\u6280\u672f\u548c\u5176\u4ed6\u950c\u79bb\u5b50\u8f7d\u4f53\uff0c\u4f7f\u7528\u5e38\u7528\u6297\u751f\u7d20\u6cbb\u7597\u591a\u836f\u8010\u836f\u7ec6\u83cc\u611f\u67d3\u3002<\/p>\n<p>PBT2\u5df2\u7ecf\u88ab\u53d1\u73b0\u53ef\u4ee5\u6253\u7834\u8bb8\u591a\u5173\u952e\u8d85\u7ea7\u7ec6\u83cc\u7684\u6297\u751f\u7d20\u8010\u836f\u6027\uff0c\u5e76\u88ab\u4e13\u5229\u8986\u76d6\u52302038\u5e74\u3002<\/p>\n<p>\u6700\u8fd1\u53d1\u8868\u5728\u5f71\u54cd\u529b\u9887\u5927\u7684\u671f\u520a\u300a\u79d1\u5b66\u8f6c\u5316\u533b\u5b66\u300b(Science Translational Medicine)\u4e0a\u7684\u7814\u7a76\u8868\u660e\uff0cPBT2\u53ef\u4ee5\u9006\u8f6c\u52a8\u7269\u8113\u6bd2\u75c7\u6a21\u578b\u4e2d\u7684\u6297\u751f\u7d20\u8010\u836f\u6027\u3002<\/p>\n<p>\u6606\u58eb\u5170\u5927\u5b66\u6559\u6388Mark Walker\u8bf4\uff0c\u8fd9\u4e9b\u7814\u7a76\u7ed3\u679c\u8868\u660ePBT2\u548c\u5176\u4ed6\u950c\u79bb\u5b50\u8f7d\u4f53\u6709\u53ef\u80fd\u5728\u4e00\u7cfb\u5217\u6297\u751f\u7d20\u4e2d\u6062\u590d\u836f\u6548\u3002<\/p>\n<p>\u6b64\u5916\uff0c\u7814\u7a76\u8868\u660e\uff0c\u66b4\u9732\u4e8ePBT2\u548c\u6297\u751f\u7d20\u4e0b\u7684\u8d85\u7ea7\u7ec6\u83cc\u4ea7\u751f\u8fdb\u4e00\u6b65\u8010\u836f\u6027\u7684\u201c\u503e\u5411\u975e\u5e38\u4f4e\u201d\u3002<\/p>\n<p>\u6839\u636eAlterity\u7684\u8bf4\u6cd5\uff0c\u8fd9\u4f7f\u5f97\u5b83\u5bf9\u65b0\u7597\u6cd5\u4ea7\u751f\u201c\u4e0d\u592a\u53ef\u80fd\u7684\u201d\u8010\u836f\u6027\u2014\u2014\u4e3aPBT2\u6cbb\u7597\u5177\u6709\u8010\u836f\u6027\u7684\u8d85\u7ea7\u7ec6\u83cc\u94fa\u5e73\u4e86\u9053\u8def\uff0c\u800c\u4e0d\u4f1a\u6210\u4e3a\u95ee\u9898\u7684\u4e00\u90e8\u5206\u3002<\/p>\n<h2>\u6297\u751f\u7d20\u8010\u836f\u6027\u65e5\u76ca\u7a81\u51fa\u7684\u5168\u7403\u6027\u95ee\u9898<\/h2>\n<p>Alterity\u8463\u4e8b\u957f\u517c\u9996\u5e2d\u6267\u884c\u5b98Geoffrey Kempler\u6307\u51fa\uff0c\u6bcf\u5e74\u670970\u4e07\u4eba\u6b7b\u4e8e\u6297\u751f\u7d20\u8010\u836f\u6027\u75c5\u539f\u4f53\u3002<\/p>\n<p>\u4e16\u754c\u536b\u751f\u7ec4\u7ec7\u5ba3\u5e03\u8010\u6297\u751f\u7d20\u7ec6\u83cc\u5bf9\u5168\u7403\u5065\u5eb7\u6784\u6210\u4e25\u91cd\u5a01\u80c1\u3002<\/p>\n<p>PBT2\u5df2\u88ab\u53d1\u73b0\u53ef\u4ee5\u6253\u7834\u4e16\u754c\u536b\u751f\u7ec4\u7ec7\u540d\u5355\u4e0a\u7684\u5927\u591a\u6570\u5173\u952e\u75c5\u539f\u4f53\u7684\u8010\u836f\u6027\u3002<\/p>\n<p>\u201c\u6211\u4eec\u7684\u5408\u4f5c\u8005\u5f00\u53d1\u7684\u65b9\u6cd5\u662f\u65b0\u9896\u7684\uff0c\u6709\u53ef\u80fd\u662f\u9769\u547d\u6027\u7684\u3002\u201d<\/p>\n<p>\u201c\u73b0\u6709\u7684\u6297\u751f\u7d20\u6b63\u5728\u5931\u53bb\u5bf9\u6297\u8fd9\u4e9b\u611f\u67d3\u7684\u80fd\u529b\uff0c\u800c\u968f\u7740\u75c5\u539f\u4f53\u4e0d\u65ad\u9002\u5e94\uff0c\u79d1\u5b66\u6b63\u5728\u52aa\u529b\u8ddf\u4e0a\u5b83\u4eec\u7684\u6b65\u4f10\u3002\u201d<\/p>\n<p>Kempler\u5148\u751f\u8bf4:\u201c\u56e0\u4e3a\u6211\u4eec\u53ef\u4ee5\u5c06PBT2\u4e0e\u73b0\u6709\u7684\u6297\u751f\u7d20\u76f8\u7ed3\u5408\uff0c\u5176\u4e2d\u8bb8\u591a\u662f\u975e\u4e13\u5229\u6297\u751f\u7d20\uff0c\u8fd9\u79cd\u65b9\u6cd5\u5bf9\u591a\u6837\u6027\u5177\u6709\u5f3a\u5927\u7684\u5546\u4e1a\u4ef7\u503c\u3002\u201d<\/p>\n<p>\u4ed6\u8865\u5145\u8bf4\uff0c\u51a0\u72b6\u75c5\u6bd2\u6269\u5927\u4e86\u8fd9\u4e00\u9700\u6c42\uff0c\u56e0\u4e3a\u4e0e\u8be5\u75be\u75c5\u76f8\u5173\u7684\u8bb8\u591a\u7ee7\u53d1\u6027\u7ec6\u83cc\u611f\u67d3\u4f1a\u5bfc\u81f4\u6b7b\u4ea1\u3002<\/p>\n<p>\u4ed6\u8bf4:\u201c\u5bf9\u6709\u6548\u6297\u83cc\u836f\u7269\u7684\u9700\u6c42\u975e\u5e38\u9ad8\u3002\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u8fd1\u65e5\uff0c\u6606\u58eb\u5170\u5927\u5b66\u7684\u5546\u7528\u8f66\u8f86UniQuest\u83b7\u5f97\u8bb8\u53ef\uff0c\u5141\u8bb8Alterity Therapeutics (ASX: ATH)\u4f7f\u7528\u5176\u950c\u79bb\u5b50\u8f7d\u4f53\u6280\u672f\u5bf9\u6297\u8d85\u7ea7\u7ec6\u83cc\u3002 UniQuest\u6388\u4e88Alterity\u5168\u7403\u72ec\u5bb6\u6743\u5229\uff0c\u4f7f\u7528\u5176\u950c\u79bb\u5b50\u8f7d\u4f53\u6280\u672f\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u65b9\u6cd5\uff0c\u4f7f\u7ec6\u83cc\u5bf9\u6297\u751f\u7d20\u91cd\u65b0\u654f\u611f\u3002 \u4e00\u65e6Alterity\u5f00\u59cb\u4ece\u8fd9\u9879\u6280\u672f\u7684\u5546\u4e1a\u5316\u4e2d\u83b7\u5f97\u5546\u4e1a\u6536\u5165\uff0c\u5b83\u5c06\u5411UniQuest\u652f\u4ed8\u91cc\u7a0b\u7891\u5f0f\u7684\u8d39\u7528\u548c\u4e0e\u5b66\u672f\u8bb8\u53ef\u76f8\u79f0\u7684\u7248\u7a0e\u3002 Alterity\u5c06\u7ed3\u5408PBT2\u950c\u79bb\u5b50\u8f7d\u4f53\u6280\u672f\u548c\u5176\u4ed6\u950c\u79bb\u5b50\u8f7d\u4f53\uff0c\u4f7f\u7528\u5e38\u7528\u6297\u751f\u7d20\u6cbb\u7597\u591a\u836f\u8010\u836f\u7ec6\u83cc\u611f\u67d3\u3002 PBT2\u5df2\u7ecf\u88ab\u53d1\u73b0\u53ef\u4ee5\u6253\u7834\u8bb8\u591a\u5173\u952e\u8d85\u7ea7\u7ec6\u83cc\u7684\u6297\u751f\u7d20\u8010\u836f\u6027\uff0c\u5e76\u88ab\u4e13\u5229\u8986\u76d6\u52302038\u5e74\u3002 \u6700\u8fd1\u53d1\u8868\u5728\u5f71\u54cd\u529b\u9887\u5927\u7684\u671f\u520a\u300a\u79d1\u5b66\u8f6c\u5316\u533b\u5b66\u300b(Science Translational Medicine)\u4e0a\u7684\u7814\u7a76\u8868\u660e\uff0cPBT2\u53ef\u4ee5\u9006\u8f6c\u52a8\u7269\u8113\u6bd2\u75c7\u6a21\u578b\u4e2d\u7684\u6297\u751f\u7d20\u8010\u836f\u6027\u3002 \u6606\u58eb\u5170\u5927\u5b66\u6559\u6388Mark Walker\u8bf4\uff0c\u8fd9\u4e9b\u7814\u7a76\u7ed3\u679c\u8868\u660ePBT2\u548c\u5176\u4ed6\u950c\u79bb\u5b50\u8f7d\u4f53\u6709\u53ef\u80fd\u5728\u4e00\u7cfb\u5217\u6297\u751f\u7d20\u4e2d\u6062\u590d\u836f\u6548\u3002 \u6b64\u5916\uff0c\u7814\u7a76\u8868\u660e\uff0c\u66b4\u9732\u4e8ePBT2\u548c\u6297\u751f\u7d20\u4e0b\u7684\u8d85\u7ea7\u7ec6\u83cc\u4ea7\u751f\u8fdb\u4e00\u6b65\u8010\u836f\u6027\u7684\u201c\u503e\u5411\u975e\u5e38\u4f4e\u201d\u3002 \u6839\u636eAlterity\u7684\u8bf4\u6cd5\uff0c\u8fd9\u4f7f\u5f97\u5b83\u5bf9\u65b0\u7597\u6cd5\u4ea7\u751f\u201c\u4e0d\u592a\u53ef\u80fd\u7684\u201d\u8010\u836f\u6027\u2014\u2014\u4e3aPBT2\u6cbb\u7597\u5177\u6709\u8010\u836f\u6027\u7684\u8d85\u7ea7\u7ec6\u83cc\u94fa\u5e73\u4e86\u9053\u8def\uff0c\u800c\u4e0d\u4f1a\u6210\u4e3a\u95ee\u9898\u7684\u4e00\u90e8\u5206\u3002 \u6297\u751f\u7d20\u8010\u836f\u6027\u65e5\u76ca\u7a81\u51fa\u7684\u5168\u7403\u6027\u95ee\u9898 Alterity\u8463\u4e8b\u957f\u517c\u9996\u5e2d\u6267\u884c\u5b98Geoffrey Kempler\u6307\u51fa\uff0c\u6bcf\u5e74\u670970\u4e07\u4eba\u6b7b\u4e8e\u6297\u751f\u7d20\u8010\u836f\u6027\u75c5\u539f\u4f53\u3002 \u4e16\u754c\u536b\u751f\u7ec4\u7ec7\u5ba3\u5e03\u8010\u6297\u751f\u7d20\u7ec6\u83cc\u5bf9\u5168\u7403\u5065\u5eb7\u6784\u6210\u4e25\u91cd\u5a01\u80c1\u3002 PBT2\u5df2\u88ab\u53d1\u73b0\u53ef\u4ee5\u6253\u7834\u4e16\u754c\u536b\u751f\u7ec4\u7ec7\u540d\u5355\u4e0a\u7684\u5927\u591a\u6570\u5173\u952e\u75c5\u539f\u4f53\u7684\u8010\u836f\u6027\u3002 \u201c\u6211\u4eec\u7684\u5408\u4f5c\u8005\u5f00\u53d1\u7684\u65b9\u6cd5\u662f\u65b0\u9896\u7684\uff0c\u6709\u53ef\u80fd\u662f\u9769\u547d\u6027\u7684\u3002\u201d \u201c\u73b0\u6709\u7684\u6297\u751f\u7d20\u6b63\u5728\u5931\u53bb\u5bf9\u6297\u8fd9\u4e9b\u611f\u67d3\u7684\u80fd\u529b\uff0c\u800c\u968f\u7740\u75c5\u539f\u4f53\u4e0d\u65ad\u9002\u5e94\uff0c\u79d1\u5b66\u6b63\u5728\u52aa\u529b\u8ddf\u4e0a\u5b83\u4eec\u7684\u6b65\u4f10\u3002\u201d Kempler\u5148\u751f\u8bf4:\u201c\u56e0\u4e3a\u6211\u4eec\u53ef\u4ee5\u5c06PBT2\u4e0e\u73b0\u6709\u7684\u6297\u751f\u7d20\u76f8\u7ed3\u5408\uff0c\u5176\u4e2d\u8bb8\u591a\u662f\u975e\u4e13\u5229\u6297\u751f\u7d20\uff0c\u8fd9\u79cd\u65b9\u6cd5\u5bf9\u591a\u6837\u6027\u5177\u6709\u5f3a\u5927\u7684\u5546\u4e1a\u4ef7\u503c\u3002\u201d \u4ed6\u8865\u5145\u8bf4\uff0c\u51a0\u72b6\u75c5\u6bd2\u6269\u5927\u4e86\u8fd9\u4e00\u9700\u6c42\uff0c\u56e0\u4e3a\u4e0e\u8be5\u75be\u75c5\u76f8\u5173\u7684\u8bb8\u591a\u7ee7\u53d1\u6027\u7ec6\u83cc\u611f\u67d3\u4f1a\u5bfc\u81f4\u6b7b\u4ea1\u3002 \u4ed6\u8bf4:\u201c\u5bf9\u6709\u6548\u6297\u83cc\u836f\u7269\u7684\u9700\u6c42\u975e\u5e38\u9ad8\u3002\u201d<\/p>\n","protected":false},"author":3,"featured_media":10413,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[403],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.3 (Yoast SEO v21.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Alterity Therapeutics\u5c06\u6253\u7834\u6297\u751f\u7d20\u8010\u836f\u6027\u7684\u6280\u672f\u5546\u4e1a\u5316<\/title>\n<meta name=\"description\" content=\"\u8fd1\u65e5\uff0c\u6606\u58eb\u5170\u5927\u5b66\u7684\u5546\u7528\u8f66\u8f86UniQuest\u83b7\u5f97\u8bb8\u53ef\uff0c\u5141\u8bb8Alterity Therapeutics (ASX: ATH)\u4f7f\u7528\u5176\u950c\u79bb\u5b50\u8f7d\u4f53\u6280\u672f\u5bf9\u6297\u8d85\u7ea7\u7ec6\u83cc\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alterity Therapeutics\u5c06\u6253\u7834\u6297\u751f\u7d20\u8010\u836f\u6027\u7684\u6280\u672f\u5546\u4e1a\u5316\" \/>\n<meta property=\"og:description\" content=\"\u8fd1\u65e5\uff0c\u6606\u58eb\u5170\u5927\u5b66\u7684\u5546\u7528\u8f66\u8f86UniQuest\u83b7\u5f97\u8bb8\u53ef\uff0c\u5141\u8bb8Alterity Therapeutics (ASX: ATH)\u4f7f\u7528\u5176\u950c\u79bb\u5b50\u8f7d\u4f53\u6280\u672f\u5bf9\u6297\u8d85\u7ea7\u7ec6\u83cc\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/alterity-therapeutics-commercialise-technology-breaks-antibiotic-resistance\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-22T01:30:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:48:04+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/12\/Alterity-Therapeutics-ATH-ASX-technology-antibiotic-resistance-zinc-ionophore.jpg\" \/>\n<meta name=\"author\" content=\"Lorna Nicholas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Alterity Therapeutics\u5c06\u6253\u7834\u6297\u751f\u7d20\u8010\u836f\u6027\u7684\u6280\u672f\u5546\u4e1a\u5316\" \/>\n<meta name=\"twitter:description\" content=\"\u8fd1\u65e5\uff0c\u6606\u58eb\u5170\u5927\u5b66\u7684\u5546\u7528\u8f66\u8f86UniQuest\u83b7\u5f97\u8bb8\u53ef\uff0c\u5141\u8bb8Alterity Therapeutics (ASX: ATH)\u4f7f\u7528\u5176\u950c\u79bb\u5b50\u8f7d\u4f53\u6280\u672f\u5bf9\u6297\u8d85\u7ea7\u7ec6\u83cc\u3002\" \/>\n<meta name=\"twitter:image\" content=\"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/12\/Alterity-Therapeutics-ATH-ASX-technology-antibiotic-resistance-zinc-ionophore.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lorna Nicholas\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/alterity-therapeutics-commercialise-technology-breaks-antibiotic-resistance\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/alterity-therapeutics-commercialise-technology-breaks-antibiotic-resistance\/\",\"name\":\"Alterity Therapeutics\u5c06\u6253\u7834\u6297\u751f\u7d20\u8010\u836f\u6027\u7684\u6280\u672f\u5546\u4e1a\u5316\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2020-12-22T01:30:10+00:00\",\"dateModified\":\"2023-08-29T17:48:04+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\"},\"description\":\"\u8fd1\u65e5\uff0c\u6606\u58eb\u5170\u5927\u5b66\u7684\u5546\u7528\u8f66\u8f86UniQuest\u83b7\u5f97\u8bb8\u53ef\uff0c\u5141\u8bb8Alterity Therapeutics (ASX: ATH)\u4f7f\u7528\u5176\u950c\u79bb\u5b50\u8f7d\u4f53\u6280\u672f\u5bf9\u6297\u8d85\u7ea7\u7ec6\u83cc\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/alterity-therapeutics-commercialise-technology-breaks-antibiotic-resistance\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/alterity-therapeutics-commercialise-technology-breaks-antibiotic-resistance\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/alterity-therapeutics-commercialise-technology-breaks-antibiotic-resistance\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alterity Therapeutics\u5c06\u6253\u7834\u6297\u751f\u7d20\u8010\u836f\u6027\u7684\u6280\u672f\u5546\u4e1a\u5316\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\",\"name\":\"Lorna Nicholas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"caption\":\"Lorna Nicholas\"},\"description\":\"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=3\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alterity Therapeutics\u5c06\u6253\u7834\u6297\u751f\u7d20\u8010\u836f\u6027\u7684\u6280\u672f\u5546\u4e1a\u5316","description":"\u8fd1\u65e5\uff0c\u6606\u58eb\u5170\u5927\u5b66\u7684\u5546\u7528\u8f66\u8f86UniQuest\u83b7\u5f97\u8bb8\u53ef\uff0c\u5141\u8bb8Alterity Therapeutics (ASX: ATH)\u4f7f\u7528\u5176\u950c\u79bb\u5b50\u8f7d\u4f53\u6280\u672f\u5bf9\u6297\u8d85\u7ea7\u7ec6\u83cc\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Alterity Therapeutics\u5c06\u6253\u7834\u6297\u751f\u7d20\u8010\u836f\u6027\u7684\u6280\u672f\u5546\u4e1a\u5316","og_description":"\u8fd1\u65e5\uff0c\u6606\u58eb\u5170\u5927\u5b66\u7684\u5546\u7528\u8f66\u8f86UniQuest\u83b7\u5f97\u8bb8\u53ef\uff0c\u5141\u8bb8Alterity Therapeutics (ASX: ATH)\u4f7f\u7528\u5176\u950c\u79bb\u5b50\u8f7d\u4f53\u6280\u672f\u5bf9\u6297\u8d85\u7ea7\u7ec6\u83cc\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/alterity-therapeutics-commercialise-technology-breaks-antibiotic-resistance\/","og_site_name":"smallcapsCN","article_published_time":"2020-12-22T01:30:10+00:00","article_modified_time":"2023-08-29T17:48:04+00:00","og_image":[{"url":"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/12\/Alterity-Therapeutics-ATH-ASX-technology-antibiotic-resistance-zinc-ionophore.jpg"}],"author":"Lorna Nicholas","twitter_card":"summary_large_image","twitter_title":"Alterity Therapeutics\u5c06\u6253\u7834\u6297\u751f\u7d20\u8010\u836f\u6027\u7684\u6280\u672f\u5546\u4e1a\u5316","twitter_description":"\u8fd1\u65e5\uff0c\u6606\u58eb\u5170\u5927\u5b66\u7684\u5546\u7528\u8f66\u8f86UniQuest\u83b7\u5f97\u8bb8\u53ef\uff0c\u5141\u8bb8Alterity Therapeutics (ASX: ATH)\u4f7f\u7528\u5176\u950c\u79bb\u5b50\u8f7d\u4f53\u6280\u672f\u5bf9\u6297\u8d85\u7ea7\u7ec6\u83cc\u3002","twitter_image":"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/12\/Alterity-Therapeutics-ATH-ASX-technology-antibiotic-resistance-zinc-ionophore.jpg","twitter_misc":{"Written by":"Lorna Nicholas"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/alterity-therapeutics-commercialise-technology-breaks-antibiotic-resistance\/","url":"https:\/\/smallcapscn.x5view.co\/alterity-therapeutics-commercialise-technology-breaks-antibiotic-resistance\/","name":"Alterity Therapeutics\u5c06\u6253\u7834\u6297\u751f\u7d20\u8010\u836f\u6027\u7684\u6280\u672f\u5546\u4e1a\u5316","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2020-12-22T01:30:10+00:00","dateModified":"2023-08-29T17:48:04+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60"},"description":"\u8fd1\u65e5\uff0c\u6606\u58eb\u5170\u5927\u5b66\u7684\u5546\u7528\u8f66\u8f86UniQuest\u83b7\u5f97\u8bb8\u53ef\uff0c\u5141\u8bb8Alterity Therapeutics (ASX: ATH)\u4f7f\u7528\u5176\u950c\u79bb\u5b50\u8f7d\u4f53\u6280\u672f\u5bf9\u6297\u8d85\u7ea7\u7ec6\u83cc\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/alterity-therapeutics-commercialise-technology-breaks-antibiotic-resistance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/alterity-therapeutics-commercialise-technology-breaks-antibiotic-resistance\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/alterity-therapeutics-commercialise-technology-breaks-antibiotic-resistance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Alterity Therapeutics\u5c06\u6253\u7834\u6297\u751f\u7d20\u8010\u836f\u6027\u7684\u6280\u672f\u5546\u4e1a\u5316"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60","name":"Lorna Nicholas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","caption":"Lorna Nicholas"},"description":"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.","url":"https:\/\/smallcapscn.x5view.co\/?author=3"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/2459"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2459"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/2459\/revisions"}],"predecessor-version":[{"id":10412,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/2459\/revisions\/10412"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/10413"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}